Compare CHRS & CEPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHRS | CEPV |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.8M | 322.4M |
| IPO Year | 2014 | N/A |
| Metric | CHRS | CEPV |
|---|---|---|
| Price | $2.00 | $10.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.51 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 57.7K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $73.08 | N/A |
| Revenue Next Year | $30.94 | N/A |
| P/E Ratio | $1.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $10.06 |
| 52 Week High | $2.62 | $10.35 |
| Indicator | CHRS | CEPV |
|---|---|---|
| Relative Strength Index (RSI) | 67.57 | 68.19 |
| Support Level | $1.55 | $10.18 |
| Resistance Level | $2.62 | $10.35 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 96.47 | 100.00 |
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Cantor Equity Partners V Inc is a blank check company.